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Eosinophils in eosinophilic pneumonia
C. Albera, P. Ghio
Idiopathic eosinophilic pneumonia (IEP) is an uncom-
mon disease of unknown aetiology characterized by the
accumulation of eosinophils in the lung, variable blood
eosinophilia and peripheral opacities on the chest radio-
gram. The response to steroid treatment is dramatic but
relapses are frequent, requiring the use of long-term
steroid treatment [1].
Eosinophils are primarily tissue cells, containing in
their granules many preformed proinflammatory and
cytotoxic mediators [2]. They are also able to synthe-
size many other substances that defend the host against
exogenous stimuli [3]; under normal conditions the
eosinophil number in those tissues that have contact with
the environment is 200–400 times greater than in the
blood [4]. An abnormally high accumulation of these
cells within the lung, frequency reaching up to 50% of
the total alveolar cell population [5], is the hallmark of
IEP, but the role of the eosinophil in the immunopatho-
genesis of lung damage in this disorder is still not com-
pletely elucidated [4].
Eosinophils accumulated within both interstitium and
small air spaces [1] are hypodense and widely degran-
ulated cells. They show typical morpho-functional char-
acteristics of activated cells and are able to damage
parenchymal lung structures by releasing a variety of
toxic substances [6]. Consequently, two major points need
to be investigated and discussed: 1) how do eosinophils
cause parenchymal injury? 2) how are eosinophils recruit-
ed and activated at the site of inflammation?
Eosinophils as effector cells in mediating 
lung damage
Cytotoxic mediators secreted by eosinophils are either
preformed, stored in specific eosinophilic granules and
released after activation (major basic protein (MBP),
eosinophilic cationic protein (ECP), eosinophil derived
neurotoxin (EDN), eosinophil peroxidase (EPO), colla-
genase, arylsulphatase B, beta-glucuronidase) or syn-
thesized de novo after activation (lipid-derived mediators,
oxygen reactive metabolites, cytokines, neuropeptides)
[3].
Of the preformed molecules, ECP seems to play the
most important role in the pathogenesis of lung dam-
age in IEP. In fact there is clear evidence of increased
alveolar levels of ECP in patients with IEP, especially
in chronic disease (chronic eosinophilic pneumonia
(CEP)) [7–9]. The finding of a significant correlation
between ECP levels and eosinophil numbers in bron-
choalveolar lavage fluid (BALF) reported by SHIJUBO
and co-workers [7] underlines the strong relationship
between the degree of eosinophilic inflammation and
the burst of eosinophil-derived toxic mediators. How-
ever, BOOMARS and co-workers [8] in this issue of the
Journal did not find such a correlation when evaluating
12 patients with CEP. They attributed this to different
proportions of activated eosinophils being present with-
in the alveolar spaces in individual patients. The sig-
nificance of these mediators in the pathogenesis of IEP
and other eosinophil-mediated diseases is underlined by
the observation that ECP levels measured in BALF in
patients with pulmonary eosinophilic granuloma are
normal [7]. In fact, in this disease the eosinophil is
thought to be present in the alveolar compartment only
as an accompanying cell, whereas the pivotal cell in the
pathogenesis of lung damage is the Langerhans cell
[10]. The observation of increased ECP levels in BALF
of idiopathic pulmonary fibrosis, which was related to
the decline in lung function [11], also suggests a pos-
sible role of this mediator in the pathogenesis of this
disease.
Recruitment and activation of eosinophils
There is increasing evidence that recruitment and ac-
tivation of eosinophil within lung tissues is under the
control of mononuclear cells. T-lymphocytes are the
source of lymphocyte chemoattractant factor (LCF) [12]
and interleukin (IL)-2 [13], the two most potent eosinophil
chemoattractants. Cytokines of the TH-2 subtype (IL-3,
IL-4, IL-5 and granulocyte macrophage colony stimu-
lating factor (GM-CSF)) regulate both recruitment and
activation of eosinophils [14].
The role of T-lymphocytes in modulating the eosino-
philic component of the alveolitis is supported by the
fact that memory and activated alveolar CD4+ T-lym-
phocytes are increased in BALF of IEP [15, 16]. This
is underlined in a study by AZUMA and co-workers [17]
in this issue of the Journal; they found a correlation be-
tween the number of activated T-lymphocytes and the
number of eosinophils in BALF. Similar findings, as
well as a correlation with the severity of the disease,
were also found in asthma [18].
The analysis of the secretory profile of these activa-
ted T-cells, performed by evaluating cytokine levels in
BALF, showed that the recruitment of eosinophils in
IEP patients could be related to an overproduction of
IL-2 (TH-1 profile) inducing a secondary increase of
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IL-5 (TH-2 profile) [19, 20], as was found in patients
treated with high doses of recombinant IL-2 [21]. These
findings could offer an explanation for the high inten-
sity eosinophilic alveolitis observed in IEP, a disease
without a clear TH-2 profile [17]. Furthermore, the in-
creased number of alveolar macrophages in BALF of
patients with active IEP [15, 17] suggests that mononu-
clear phagocytes, either directly or by cooperation with
alveolar T-lymphocytes, could exert further regulatory
activities on both eosinophil recruitment and activation.
The modulation of adhesion molecule expression is
another way by which both the influx and the activa-
tion of inflammatory cells into the target organs and tis-
sues are regulated. Eosinophils bind to their adhesion
ligands in the extracellular matrix and migrate through
vascular endothelial cells [22, 23]; they are then acti-
vated by binding to fibronectin (in a dose and time-
dependent manner) leading to degranulation [24] and
release of increased amounts of both leukotriene C4(LTC4) [25] and reactive oxygen species [26]. The adhe-
sion to fibronectin and the subsequent activation of
eosinophils are dependent upon, and consequently reg-
ulated by, the expression of very late activation antigen
4 (VLA-4) on the cell surface [26], and enhanced by sol-
uble intercellular adhesion molecule-1 (ICAM-1) [27].
In addition, the adhesion of eosinophils to fibronectin
prolongs their survival [28]. As far as the preferential
expression of adhesion molecules on locally accumu-
lated eosinophils in IEP is concerned, it has recently
been demonstrated that the expression of certain adhe-
sion molecules (CD11a, CD11b, CD18, CD49d, CD62L)
is lower for BALF eosinophils than for circulating
ones; the CD54 (ICAM-1) molecule is expressed only
by alveolar eosinophils [17].
Peripheral blood eosinophils from both healthy and
asthmatic subjects synthesize and release IL-3, IL-5,
GMCSF and IL-8 [29–31] after stimulation and, in par-
ticular, after chemoattractant challenge [32]. The ability
of eosinophils to produce and release these cytokines
confirms the role of the activated eosinophil as an effec-
tor cell. This cytokine-mediated network, the increase
of human leucocyte antigen-DR (HLA-DR) expression
on activated eosinophils [15] and the expression of the
CD4 molecule by eosinophils [33] suggests that the
interaction with activated alveolar antigen presenting
cells could also be a pathogenetic mechanism for eosinophil
recruitment and activation.
Heterogeneity of eosinophil recruitment 
and activation
SAITA et al. [34], by evaluating 5 patients with IEP
and peripheral blood eosinophilia, demonstrated that
circulating eosinophils show a heterogenous chemotac-
tic response to 5 different T-cell-derived eosinophil che-
motactic factors (ECFs). Eosinophils of two patients
responded to five ECFs, whereas those of the other three
patients failed to respond to one of these ECFs (ECF-
PI 9). The lack of responsiveness to ECF-PI 9, was as-
sociated with a favourable clinical and radiological
outcome of the diseases, accompanied by a reduction of
lung infiltrating eosinophils after steroid treatment.
KITA et al. [20] recently showed that in IEP the num-
ber of eosinophils in affected lobes was 70 times higher
than in unaffected ones. This preferential accumulation
was accompanied by a corresponding local increase of
eosinophil-active cytokines (IL-5, IL-6 and IL-10) which
were virtually absent in uninvolved lobes and in peri-
pheral blood.
ALOUI et al. [35] observed that eosinophils isolated
from BAL in one case of CEP produced high levels of
oxygen free radicals and exhibited an increased level of
cyclic adenosine monophosphate (cAMP) deaminase
phosphodiesterase (PDE). The PDE activity in this pati-
ent was preferentially located in the plasma membrane,
whilst the PDE activity of eosinophils in asthmatic and
healthy subjects was predominantly located in the cyto-
sol. This difference could be due to: a) the presence of
a particular PDE isoform that binds to the eosinophil
membrane in CEP; b) the presence of an abnormal PDE
protein only in CEP; c) a translocation of PDE activity
from the cytosol to the membrane during cell activa-
tion. The first two hypotheses seem to be the more intrigu-
ing ones.
Analysis of above data suggests that this heterogen-
eity, which is able to influence both the site and the
amount of accumulation of eosinophils within the lung,
could be related either to the presence of different cir-
culating eosinophil populations or to the generation of
clones of T-lymphocytes that preferentially produce dif-
ferent chemoattractants and regulatory molecules. Possi-
ble explanations for this heterogeneity include genetic
differences, previous eosinophil priming which modi-
fied eosinophil structures (adhesion molecules, cell plas-
ticity) and a selective activation of T-cell clones related
to an altered accessory function of alveolar mononu-
clear phagocytes.
A knowledge of the immunological network involv-
ing both cells and mediators offers an explanation of
the dramatic response of IEP to steroid therapy as well
as a suggestion for new therapeutic strategies that could
be able not only to rapidly reduce eosinophilic infiltra-
tion of parenchymal structures, but also to prevent the
frequent relapses and the long-lasting need for steroid
treatment, by inhibiting possible self-maintaining eosino-
philic inflammation. This aim could be achieved by
employing specific cytokine or chemoattractant recep-
tor antagonists, or by acting on other mechanisms such
as cAMP PDE activity.
In conclusion, the picture of the pathogenetic role of
eosinophils in idiopathic eosinophilic pneumonia, even
if frameless and still blurred, is becoming clearer. The
eosinophil is the principal effector cell and seems to be
involved in both the regulation and the persistence of
the inflammatory processes. Alongside the eosinophil,
the T-lymphocyte is the cell that primarily regulates
both recruitment and activation of the eosinophil. In the
background is the alveolar macrophage, which proba-
bly plays a regulatory role either directly or by inter-
acting with T-lymphocytes. In the next few years, it is
probable that further data will become available that
may shed light upon the role of the alveolar macrophage.
References
1. Carrington CB, Addington WW, Goff AH, et al. Chro-
nic eosinophilic pneumonia. N Engl J Med 1969; 280:
787–798.
C. ALBERA, P. GHIO2438
2. Gleich GJ, Adolphson CR. The eosinophil leucocyte:
structure and function. Adv Immunol 1986; 39: 177–253.
3. Kroegel C, Virchow Jr JC, Luttmann W, Walker C, Warner
JA. Pulmonary immune cells in health and disease: the
eosinophil leucocyte (part I). Eur Respir J 1994; 7:
515–543.
4. Lopez M. Eosinophilic pneumonia. Ann Allergy 1993;
71: 338–339.
5. Allen JN, Davis WB. Eosinophilic lung diseases. Am J
Respir Crit Care Med 1994; 150: 1423–1438.
6. Gonzales EB, Swedo JL, Rajaraman S, Daniels JC,
Grant JA. Ultrastructural and immunohistochemical evi-
dence for release of eosinophilic granules in vivo: cyto-
toxic potential in chronic eosinophilic pneumonia. J
Allergy Clin Immunol 1986; 79: 755–762.
7. Shijubo N, Shigehara K, Hirasawa H, Inuzuka M, Abe
S. Eosinophilic cationic protein in chronic eosinophilic
pneumonia and eosinophilic granuloma. Chest 1994; 106:
1481–1486.
8. Boomars KA, van Velzen-Blad H, Mulder PGH,
Koenderman L, Lammers J-WJ, van den Bosch JMM.
Eosinophilic cationic protein and immunoglobulin lev-
els in bronchoalveolar lavage fluid obtained from patients
with chronic eosinophilic pneumonia. Eur Respir J
1996; 9: 2488–2493.
9. Janin A, Torpier G, Courtin P, et al. Segregation of
eosinophil proteins in alveolar macrophage compart-
ments in chronic eosinophilic pneumonia. Thorax 1993;
48: 57–62.
10. Hance AJ, Cadranel J, Soler P, Basset F. Pulmonary and
extrapulmonary Langerhans cell granulomatosis (histio-
cytosis X). Semin Respir Med 1988; 9: 349–368.
11. Hallgren R, Bjermer L, Lundgren R, Venge P. The
eosinophil component of the alveolitis in idiopathic pul-
monary fibrosis. Am Rev Respir Dis 1989; 139: 373–
397.
12. Cruikshank WW, Berman JS, Theodore AC, Bernado J,
Center DM. Lymphocyte chemoattractant factor (LCF)
induces CD4-dependent intracytoplasmic signalling in
lymphocytes. J Immunol 1991; 146: 2928–2934.
13. Rand TH, Silberstein DS, Kornfeld H, Weller PF.
Human eosinophils express functional interleukin-2 rec-
eptors. J Clin Invest 1991; 88: 825–832.
14. Weller PF, Lim K, Wan HC, et al. Role of the eosino-
phil in allergic reactions. Eur Respir J 1996; 9: Suppl
22: 1095–1159.
15. Albera C, Ghio P, Solidoro P, Mabritto I, Marchetti L,
Pozzi E. Activated and memory alveolar T-lymphocytes
in idiopathic eosinophilic pneumonia. Eur Respir J
1995; 8: 1281–1285.
16. Walker C, Bauer W, Braun RK, et al. Activated T-cells
and cytokines in bronchoalveolar lavages from patients
with various lung disease associated with eosinophilia.
Am J Respir Crit Care Med 1994; 150: 1038–1048.
17. Azuma M, Nakamura Y, Sano T, Chano Y, Sone S.
Adhesion molecule expression on eosinophils in idio-
pathic eosinophilic pneumonia. Eur Respir J 1996; 9:
2494–2500.
18. Walker C, Kaegi MK, Braun MD, Blasek K. Activated
T-cells and eosinophilia in bronchoalveolar lavages
from subjects with asthma correlated with disease seve-
rity. J Allergy Clin Immunol 1991; 89: 958–967.
19. Yamaguchi Y, Suda T, Shiozaki H, et al. Role of IL-5
in IL-2 induced eosinophilia. In vivo and in vitro ex-
pression of IL-5 mRNA by IL-2. J Immunol 1990; 145:
873–877.
20. Kita H, Sur S, Hunt LW, et al. Cytokine production at
the site of disease in chronic eosinophilic pneumonitis.
Am J Respir Crit Care Med 1996; 153: 1437–1441.
21. van Haelst Pisani C, Kovach JS, Kita H, et al. Admini-
stration of interleukin-2 results in increased plasma con-
centration of IL-5 and eosinophilia in patients with
cancer. Blood 1991; 78: 1538–1544.
22. Neeley SP, Hamann KJ, White SR, Baranowski SL,
Burch RA, Leff AR. Selective regulation of expression
of surface adhesion molecules Mac-1, L-selectin and
VLA-4 on human eosinophils and neutrophils. Am J
Cell Mol Biol 1993; 8: 633–639.
23. Laudanna C, Melotti P, Bonizzato C, et al. Ligation of
members of the beta-1 or the beta-2 subfamilies of inte-
grins by antibodies triggers eosinophil respiratory burst
and spreading. Immunology 1993; 80: 273–280.
24. Neeley SP, Hamann KJ, Dowling TL, McAllister KT,
White SR, Leff AR. Augmentation of stimulated eosi-
nophil degranulation by VLA-4 (CD49d)-mediated adhe-
sion to fibronectin. AM J Respir Cell Mol Biol 1994;
11: 206–213.
25. Yoshida K, Suko M, Matsuzaki G, Sugiyama M, Okudaira
H, Ito K. Effect of fibronectin on the production of
leukotriene C4 by eosinophils. Int Arch Allergy Immu-
nol 1995; 108: Suppl. 1: 50–51.
26. Higashimoto I, Chihara J, Kakazu T, Yamamoto T,
Kurachi D, Nakajima S. Adhesion to fibronectin aug-
ments eosinophil radical oxygen products. Int Arch Al-
lergy Immunol 1995; 108: Suppl. 1: 48–49.
27. Chihara J, Kakazu T, Higashimoto I, Yamamoto T,
Kurachi D, Nakajima S. Increased eosinophil oxidative
metabolism by treatment with soluble intercellular
adhesion molecule-1. Int Arch Allergy Immunol 1995;
108: Suppl. 1: 45–47.
28. Anwer ARF, Mogbel R, Walsh GM, Kay AB, Wardlaw
AJ. Adhesion to fibronectin prolongs eosinophil sur-
vival. J Exp Med 1993; 177: 839–843.
29. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS,
Gleich GJ. Granulocyte-macrophage colony stimulating
factor and interleukin-3 release from human peripheral
blood eosinophils and neutrophils. J Exp Med 1991;
174: 745–748.
30. Broide DM, Paine MM, Firestein GS. Eosinophils express
interleukin 5 and granulocyte/macrophage colony stim-
ulating factor mRNA at sites of allergic inflammation
in asthmatics. J Clin Invest 1992; 90: 1414–1424.
31. Braun RK, Franchini M, Erard F, et al. Human periphe-
ral blood eosinophils produce and release interleukin-8
on stimulating with calcium ionophore. Eur J Immunol
1993; 23: 956–960.
32. Miyamasu M, Hirai K, Takahashi Y, et al. Induction of
eosinophil cytokine generation by chemoattractants. Int
Arch Allergy Immunol 1995; 108: Suppl. 1: 12–15.
33. Rand TH, Cruikshank WW, Center DH, Weller PF.
CD4 mediated stimulation of human eosinophils: lym-
phocyte chemoattractant factor and other CD4-binding
ligands elicit eosinophil migration. J Exp Med 1991;
173: 1521–1528.
34. Saita N, Hirayama S, Sugimoto M, Ando M, Hirashima
M. Chemotactic heterogeneity of eosinophils in idio-
pathic pulmonary eosinophilia. Int Arch Allergy Immu-
nol 1995; 108 Suppl. 1: 25–27.
35. Aloui R, Gormand F, Prigent AF, Perrin-Fayolle M,
Pacheco Y. Increased respiratory burst and phosphodi-
esterase activity in alveolar eosinophils in chronic eo-
sinophilic pneumonia. Eur Respir J 1996; 9: 377–379.
EOSINOPHILS IN EOSINOPHILIC PNEUMONIA 2439
